The strategy consisting of targeting all class I PI3Ks with pan-PI3K inhibitors rapidly showed limitations due to toxicities in combination treatments and an increased resistance to treatment [8], emphasizing the need to specifically target the key PI3K isoforms in each cancer subtype [4]. This evidence concerns the gene PIK3CB and cancer.